Drawing for KD-PÜR

USPTO serial 79294557

KD-PÜR

Reviewed by CopyMark Law Group

Reg. 6674408Status 700Registered
Filing date
Status date
Registration date
Mar 22, 2022
Examiner
CLARKE, NANCY
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with KD-PÜR?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Christian Wolff

Christian Wolff Schock Rechtsanwaelte GbRFeldmannstr. 121Saarbruecken, 66119GERMANY

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and veterinary products, namely, pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders, pharmaceutical products for the prevention and treatment of cancer, pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines, and chemical reagents for medical or veterinary purposes; sanitary preparations for medical use; dietetic foodstuffs and preparations for medical or veterinary purposes, namely, dietetic foods and beverages adapted for medical use, dietetic foods adapted for veterinary use, dietetic beverages adapted for veterinary use, and dietetic preparations adapted for medical purposes; dietary supplements for humans and animals; pharmaceutical products in the nature of oils, powders and capsules containing omega-3-extracts for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; nutritional supplements; dietetic preparations adapted for medical purposes containing omega-3-extracts and in the form of oils, powders and capsules containing omega-3-extractsACTIVE—
040Contract manufacturing for others of pharmaceutical products, dietary supplements and dietetic products for medical purposes containing omega-3-extracts in the form of oils, powders and capsulesACTIVE—
042Scientific and technological services, namely, pharmaceutical research and development, pharmaceutical products development, testing of pharmaceuticals, development of pharmaceutical preparations and medicines, scientific research in the field of pharmaceuticals, pharmaceutical research services, laboratory research services relating to pharmaceuticals, scientific analysis in the field of nutritional supplements; scientific research and development in the field of lipid extraction from natural resources; scientific laboratory services; chemical laboratories; scientific and industrial research for others relating to the manufacture of pharmaceutical products, dietary supplements and dietetic products for medical purposes containing omega-3-extracts in the form of oils, powders and capsulesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 5, 2022FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Aug 16, 2022FICSFINAL DISPOSITION NOTICE SENT TO IB—
Aug 16, 2022FIMPFINAL DISPOSITION PROCESSED—
Jun 22, 2022FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 22, 2022R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 21, 2022OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Mar 2, 2022OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 2, 2022OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Jan 22, 2022GPNXNOTIFICATION PROCESSED BY IB—
Jan 4, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 4, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 15, 2021OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Dec 15, 2021OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Dec 15, 2021NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 27, 2021CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 26, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 25, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 25, 2021ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Jun 1, 2021DMCCDATA MODIFICATION COMPLETED—
Jun 1, 2021GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jun 1, 2021GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 1, 2021CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 1, 2021ALIEASSIGNED TO LIE—
May 6, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 6, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 6, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 13, 2020RFNTREFUSAL PROCESSED BY IB—
Nov 25, 2020RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Nov 24, 2020RFRRREFUSAL PROCESSED BY MPU—
Nov 8, 2020RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Nov 7, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 6, 2020DOCKASSIGNED TO EXAMINER—
Oct 3, 2020MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 29, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 24, 2020REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance